Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.

@article{Souness1997ProposalFP,
  title={Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.},
  author={John E. Souness and S. Prahlada Rao},
  journal={Cellular signalling},
  year={1997},
  volume={9 3-4},
  pages={
          227-36
        }
}
cAMP-specific phosphodiesterase inhibitors display a range of activities in vitro and in vivo which suggest they may be useful in the treatment of inflammatory diseases. However, these compounds elicit a number of side-effects which may limit their therapeutic potential. Certain side-effects of PDE4 inhibitors such as emesis and gastric acid secretion are associated with their actions at a high affinity rolipram binding site (HARBS). In contrast, a number of anti-inflammatory actions of PDE4… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 42 CITATIONS

Preventive Effect of Zaprinast and 3-Isobutyl, 1-Methylxanthine (Phosphodiesterase Inhibitors) on Gastric Injury Induced by Nonsteroidal Antiinflammatory Drugs in Rats

Juan Manuel Herrerias, José M. Esteban, +6 authors Pilar Esteban
  • Digestive Diseases and Sciences
  • 2003
VIEW 10 EXCERPTS
HIGHLY INFLUENCED

Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action.

  • Handbook of experimental pharmacology
  • 2011
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Small molecule allosteric modulators of phosphodiesterase 4.

  • Handbook of experimental pharmacology
  • 2011
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2019